Omega Therapeutics is delveoping an approach to use mRNA therapeutics as programmable epigenetic medicines by utilizing its OMEGA Epigenomic Programming platform. Co. designs and engineers its mRNA therapeutics, which are programmable and modular epigenetic medicines, called Omega Epigenomic Controllers (OECs) to target EpiZips for Precision Genomic Control. Co.'s pipeline consists of early-stage, preclinical programs that span oncology, multigenic diseases. Co. has conducted in vivo preclinical studies of its OECs in multiple disease models for various indications, including hepatocellular carcinoma, non-small cell lung cancer, and acute respiratory distress syndrome. The OMGA average annual return since 2021 is shown above.
The Average Annual Return on the OMGA average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether OMGA average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the OMGA average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|